Kenvue Inc., the maker of Tylenol, beat Wall Street estimates for first-quarter revenue and profit on Thursday. The positive performance was driven by robust sales in its skin health and beauty brands.
Key Financial Highlights
-
Earnings: Adjusted earnings per share (EPS) came in at 32 cents, surpassing the 26 cents expected by analysts.
-
Revenue: Quarterly net sales reached $3.91 billion, a 4.5% year-over-year increase, beating estimates of $3.84 billion.
-
Core Segments: The skin health and beauty unit, which includes Neutrogena and Aveeno, rose 8.4% to $1.06 billion, supported by strong worldwide demand.
Progress on the $40 Billion Buyout Kenvue is currently in the middle of a $40 billion merger with Kimberly-Clark.
-
Closing Timeline: CEO Kirk Perry confirmed the deal is expected to close in the second half of 2026.
-
Restructuring: The company expects to incur approximately $250 million in pre-tax restructuring expenses and other charges this year as part of its business transformation and preparation for the merger.
Analyst Sentiment While Kenvue’s tenure as a public company has been described as “tumultuous,” analysts at RBC Capital Markets called the first-quarter results bullish for Kimberly-Clark. Kenvue’s fundamentals appear to be stabilizing, though near-term focus will likely remain on the merger process and ongoing litigation headlines.